Verastem Oncology Announces Proposed Public Offering Of Common Stock And Pre-Funded Warrants; No Terms Disclosed
Portfolio Pulse from Benzinga Newsdesk
Verastem Oncology (NASDAQ:VSTM) announces a proposed public offering of common stock and pre-funded warrants. The company plans to use the net proceeds for research and development, potential launch of avutometinib and defactinib in low-grade serous ovarian cancer, and working capital.
June 15, 2023 | 8:00 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Verastem Oncology's proposed public offering of common stock and pre-funded warrants may impact its stock price in the short term.
The announcement of a public offering of common stock and pre-funded warrants may lead to dilution of existing shares, which could negatively impact the stock price in the short term. Additionally, the uncertainty surrounding the completion, size, and terms of the offering may create volatility in the stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100